Faraha Ahmed

New Delhi, DL 110062, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Alogliptin-metformin synergy ameliorates diabetes-associated bone loss via modulation of DPP-4 activity and OPG/RANKL signaling.

Alogliptin-metformin synergy ameliorates diabetes-associated bone loss via modulation of DPP-4 activity and OPG/RANKL signaling.

Journal: 3 Biotech

Published: January 21, 2026

Development, synthesis and preclinical evaluation of naringenin and its semi-synthetic derivatives in postmenopausal osteoporosis.

Development, synthesis and preclinical evaluation of naringenin and its semi-synthetic derivatives in postmenopausal osteoporosis.

Journal: Natural product research

Published: October 16, 2025

Proteases and Osteoporosis: A Comprehensive Review of Their Role in Bone Health.

Proteases and Osteoporosis: A Comprehensive Review of Their Role in Bone Health.

Journal: Current drug targets

Published: November 04, 2024

Tauopathy in AD: Therapeutic Potential of MARK-4.

Tauopathy in AD: Therapeutic Potential of MARK-4.

Journal: Current Alzheimer research

Published: September 17, 2024

Targeting dipeptidyl peptidase-8/9 to combat inflammation-induced osteoclastogenesis in RAW264.7 macrophages and analysis of anti-osteoclastogenesis potential of chrysin.

Targeting dipeptidyl peptidase-8/9 to combat inflammation-induced osteoclastogenesis in RAW264.7 macrophages and analysis of anti-osteoclastogenesis potential of chrysin.

Journal: Iranian journal of basic medical sciences

Published: August 29, 2024

Unravelling the role of dipeptidyl peptidases-8/9 (DPP-8/9) in inflammatory osteoporosis: a comprehensive study investigating chrysin as a potential anti-osteoporotic agent.

Unravelling the role of dipeptidyl peptidases-8/9 (DPP-8/9) in inflammatory osteoporosis: a comprehensive study investigating chrysin as a potential anti-osteoporotic agent.

Journal: The Journal of pharmacy and pharmacology

Published: February 22, 2024

Osteogenic effect of alogliptin in chemical-induced bone loss: a tri-modal in silico, in vitro, and in vivo analysis.

Osteogenic effect of alogliptin in chemical-induced bone loss: a tri-modal in silico, in vitro, and in vivo analysis.

Journal: The Journal of pharmacy and pharmacology

Published: February 22, 2024

Phytochemicals and Nanotechnology: A Powerful Combination against Breast Cancer.

Phytochemicals and Nanotechnology: A Powerful Combination against Breast Cancer.

Journal: Mini reviews in medicinal chemistry

Published: December 07, 2023

Utilization of Nanotechnology to Improve Bone Health in Osteoporosis Exploiting Nigella sativa and Its Active Constituent Thymoquinone.

Utilization of Nanotechnology to Improve Bone Health in Osteoporosis Exploiting Nigella sativa and Its Active Constituent Thymoquinone.

Journal: Bioengineering (Basel, Switzerland)

Published: September 05, 2022

Immunology of osteoporosis: relevance of inflammatory targets for the development of novel interventions.

Immunology of osteoporosis: relevance of inflammatory targets for the development of novel interventions.

Journal: Immunotherapy

Published: June 29, 2022

Recent Advances in Theranostic Applications of Nanomaterials in Cancer.

Recent Advances in Theranostic Applications of Nanomaterials in Cancer.

Journal: Current pharmaceutical design

Published: March 17, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026